Skip to Content

Ongentys Approval History

FDA Approved: Yes (First approved April 24, 2020)
Brand name: Ongentys
Generic name: opicapone
Dosage form: Capsules
Company: Neurocrine Biosciences, Inc.
Treatment for: Parkinson's Disease

Ongentys (opicapone) is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.

Development History and FDA Approval Process for Ongentys

DateArticle
Apr 27, 2020Approval FDA Approves Ongentys (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
Jul 10, 2019Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
Feb 14, 2018Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide